Pestalozzi advised Roth Capital Partners in connection with underwriting of USD 10 million public offering of Auris Medical
Auris Medical Holding AG, a Swiss clinical-stage company listed at NASDAQ (EARS) and dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, closed a public offering of 10,000,000 common shares and 10,000,000 warrants, each warrant entitling its holder to purchase 0.70 of a common share. The common shares and warrants were sold in units comprised of one common share and one warrant at a public offering price of USD 1.00 per unit. Auris Medical Holding AG also closed the sale of an additional 1,350,000 warrants pursuant to the underwriter's partial exercise of its 30-day option to purchase up to 1,500,000 additional common shares and/or 1,500,000 additional warrants at the public offering price less underwriting discounts. Roth Capital Partners acted as sole book-running manager in the offering. Pestalozzi advised Roth Capital Partners as to Swiss law.